Novo Nordisk and Eli Lilly shares both fall after Novo’s price-cut plan for Ozempic and Wegovy
The anticipated price reductions for Ozempic and Wegovy have led to declines in Novo Nordisk and Eli Lilly shares, reflecting investor concerns about...
Read Full Article →